Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
ASCEND Therapeutics
With
Solvay Pharmaceuticals
The primary objective of this study was to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause by comparing the efficacy of 0.9 g and 1.25 g EstroGel® 0.03% doses with placebo. Effects on symptoms of vulvar and vaginal atrophy were assessed as secondary efficacy parameters.
Age
45–65
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Women 45-65 years
naturally or surgically postmenopausal
experiencing hot flushes
You may not be if
hypersensitivity to estrogen replacement therapy
pregnancy or lactating
abnormal PAP smear
history/suspected cervical, uterine, adrenal, pituitary, breast or ovarian malignancy
